Nintedanib is an inhibitor of tyrosine kinases involved in the progression of pulmonary fibrosis and blocks the signalling pathways involved in fibrotic processes. We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) around the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung disease and the evidence supporting the investigation of nintedanib in this indication.
The abstract ‘Nintedanib in children and adolescents with fibrosing interstitial lung disease: the InPedILD trial.‘ was presented at ERS 2022, 4–6 September, 2022.
Questions
- Could you give us a brief overview of the incidence, prognosis and unmet needs in the treatment of childhood interstitial lung disease? (0:34)
- What evidence supports the investigation of nintedanib treatment for children and adolescents with fibrosing ILD? (3:32)
Disclosures: Robin Deterding discloses consulting for Boehringer Ingelheim; receiving grant/ research support from Boehringer Ingelheim; and serving on advisory boards for Boehringer Ingelheim.Â
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
